A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways

BMC Cancer

Juan Liu¹  Xionghui Zhou¹ 

[1]School of Computer, Wuhan University, Wuhan, P.R. China

关键词: Immune system;    Prediction model;    Dysregulated pathways;    Breast cancer;    Bone metastasis;   

Others  :  1121295
DOI  :  10.1186/1471-2407-14-618

 received in 2014-02-15, accepted in 2014-08-20,  发布年份 2014

【 摘 要 】

Background

Although there are a lot of researches focusing on cancer prognosis or prediction of cancer metastases, it is still a big challenge to predict the risks of cancer metastasizing to a specific organ such as bone. In fact, little work has been published for such a purpose nowadays.

Methods

In this work, we propose a Dysregulated Pathway Based prediction Model (DPBM) built on a merged data set with 855 samples. First, we use bootstrapping strategy to select bone metastasis related genes. Based on the selected genes, we then detect out the dysregulated pathways involved in the process of bone metastasis via enrichment analysis. And then we use the discriminative genes in each dysregulated pathway, called as dysregulated genes, to construct a sub-model to forecast the risk of bone metastasis. Finally we combine all sub-models as an ensemble model (DPBM) to predict the risk of bone metastasis.

Results

We have validated DPBM on the training, test and independent sets separately, and the results show that DPBM can significantly distinguish the bone metastases risks of patients (with p-values of 3.82E-10, 0.00007 and 0.0003 on three sets respectively). Moreover, the dysregulated genes are generally with higher topological coefficients (degree and betweenness centrality) in the PPI network, which means that they may play critical roles in the biological functions. Further functional analysis of these genes demonstrates that the immune system seems to play an important role in bone-specific metastasis of breast cancer.

Conclusions

Each of the dysregulated pathways that are enriched with bone metastasis related genes may uncover one critical aspect of influencing the bone metastasis of breast cancer, thus the ensemble strategy can help to describe the comprehensive view of bone metastasis mechanism. Therefore, the constructed DPBM is robust and able to significantly distinguish the bone metastases risks of patients in both test set and independent set. Moreover, the dysregulated genes in the dysregulated pathways tend to play critical roles in the biological process of bone metastasis of breast cancer.

【 授权许可】

   
2014 Zhou and Liu; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Landemaine T, Jackson A, Bellahcene A, Rucci N, Sin S, Abad BM, Sierra A, Boudinet A, Guinebretiere JM, Ricevuto E, Nogues C, Briffod M, Bieche I, Cherel P, Garcia T, Castronovo V, Teti A, Lidereau R, Driouch K: A six-gene signature predicting breast cancer lung metastasis. Cancer Res 2008, 68(15):6092-6099.
• [2]Santini D, Galluzzo S, Zoccoli A, Pantano F, Fratto ME, Vincenzi B, Lombardi L, Gucciardino C, Silvestris N, Riva E, Rizzo S, Russo A, Maiello E, Colucci G, Tonini G: New molecular targets in bone metastases. Cancer Treat Rev 2010, 36:S6-S10.
• [3]Smid M, Wang YX, Klijn JGM, Sieuwerts AM, Zhang Y, Atkins D, Martens JWM, Foekens JA: Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006, 24(15):2261-2267.
• [4]Kominsky SL, Davidson NE: A “bone” fide predictor of metastasis? Predicting breast cancer metastasis to bone. J Clin Oncol 2006, 24(15):2227-2229.
• [5]Korde LA, Gralow JR: Can we predict who’s at risk for developing bone metastases in breast cancer? J Clin Oncol 2011, 29(27):3600-3604.
• [6]Roodman GD: Mechanisms of disease: mechanisms of bone metastasis. New Engl J Med 2004, 350(16):1655-1664.
• [7]Weigelt B, Hu ZY, He XP, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, van’t Veer LJ: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005, 65(20):9155-9158.
• [8]Harrell JC, Prat A, Parker JS, Fan C, He XP, Carey L, Anders C, Ewend M, Perou CM: Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Tr 2012, 132(2):523-535.
• [9]Kang YB, Siegel PM, Shu WP, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549.
• [10]Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ: Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Tr 2013, 137(2):631-636.
• [11]Sanz-Pamplona R, Garcia-Garcia J, Franco S, Messeguer X, Driouch K, Oliva B, Sierra A: A taxonomy of organ-specific breast cancer metastases based on a protein-protein interaction network. Mol Biosyst 2012, 8(8):2085-2096.
• [12]Chuang HY, Lee E, Liu YT, Lee D, Ideker T: Network-based classification of breast cancer metastasis. Mol Syst Biol 2007, 3:140.
• [13]Venet D, Dumont JE, Detours V: Most random gene expression signatures are significantly associated with breast cancer outcome. Plos Comput Biol 2011, 7(10):e1002240.
• [14]Zhou X, Liu J, Xiong J: Predicting distant metastasis in breast cancer using ensemble classifier based on context-specific miRNA regulation modules. In Bioinformatics and Biomedicine (BIBM), 2012 IEEE International Conference on. Philadelphia, PA: IEEE; 2012:1-6.
• [15]Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, Bull S, Pawson T, Morris Q, Wrana JL: Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 2009, 27(2):199-204.
• [16]Van Vliet MH, Klijn CN, Wessels LF, Reinders MJ: Module-based outcome prediction using breast cancer compendia. PLoS One 2007, 2(10):e1047.
• [17]Abraham G, Kowalczyk A, Loi S, Haviv I, Zobel J: Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics 2010, 11:277. BioMed Central Full Text
• [18]Lee E, Chuang HY, Kim JW, Ideker T, Lee D: Inferring pathway activity toward precise disease classification. Plos Comput Biol 2008, 4(11):e1000217.
• [19]Wang YX, Klijn JGM, Zhang Y, Sieuwerts A, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D, Foekens JA: Gene-expression pro-files to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679.
• [20]Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu WP, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524.
• [21]Bos PD, Zhang XHF, Nadal C, Shu WP, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J: Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459(7249):1005-U1137.
• [22]van de Vijver MJ, He YD, van ’t Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009.
• [23]Schaefer MH, Fontaine JF, Vinayagam A, Porras P, Wanker EE, Andrade-Navarro MA: HIPPIE: Integrating protein interaction networks with experiment based quality scores. Plos One 2012, 7(2):e31826.
• [24]Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. P Natl Acad Sci USA 2005, 102(43):15545-15550.
• [25]Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart MT, Delorenzi M: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer I 2006, 98(4):262-272.
• [26]Moreau Y, Tranchevent LC: Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nat Rev Genet 2012, 13(8):523-536.
• [27]Hase T, Tanaka H, Suzuki Y, Nakagawa S, Kitano H: Structure of protein interaction networks and their implications on drug design. Plos Comput Biol 2009, 5(10):e1000550.
• [28]Yao LX, Rzhetsky A: Quantitative systems-level determinants of human genes targeted by successful drugs. Genome Res 2008, 18(2):206-213.
• [29]Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M: Computing topological parameters of biological networks. Bioinformatics 2008, 24(2):282-284.
• [30]Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57.
• [31]Nicolini A, Carpi A, Rossi G: Cytokines in breast cancer. Cytokine Growth F R 2006, 17(5):325-337.
• [32]Ben-Baruch A: Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastas 2008, 25(4):345-356.
• [33]Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V: CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immun 2008, 57(4):541-548.
• [34]Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
• [35]Ara T, DeClerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010, 46(7):1223-1231.
• [36]Li XH, Lomini C, Hyink D, Wilson PD: PRKX critically regulates endothelial cell proliferation, migration, and vascular-like structure formation. Dev Biol 2011, 356(2):475-485.
• [37]Zlotnik A, Burkhardt AM, Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011, 11(9):597-606.
• [38]Michalides R: Cell cycle regulators: role in etiology, prognosis and treatment in cancer. Ann Oncol 2002, 13:39.
• [39]Dass CR, Tan ML, Galloway SJ, Choong PF: Dz13 induces a cytotoxic stress response with upregulation of E2F1 in tumor cells metastasizing to or from bone. Oligonucleotides 2010, 20(2):79-91.
• [40]Janssens K, Ten Dijke P, Janssens S, Van Hul W: Transforming growth factor-β1 to the bone. Endocr Rev 2005, 26(6):743-774.
• [41]Bonapasta SA, Gregori M, Lanza R, Sangiorgi E, Menghi A, Scarpini M, Modesti M: Metastasis to the Pancreas from Breast Cancer: Difficulties in Diagnosis and Controversies in Treatment. Breast Care 2010, 5(3):170-172.
• [42]Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS: Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012, 18(8):1224-1231.
• [43]Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440(7084):692-696.
• [44]DeNardo DG, Johansson M, Coussens LM: Immune cells as mediators of solid tumor metastasis. Cancer Metast Rev 2008, 27(1):11-18.
• [45]Bewick M, Conlon M, Parissenti AM, Lee H, Zhang L, Gluck S, Lafrenie RM: Cutting edge communication - Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematoth Stem Cell 2001, 10(6):759-768.
• [46]Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6(5):1755-1766.
• [47]Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411(6835):342-348.
• [48]Friedl P, Gilmour D: Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Bio 2009, 10(7):445-457.
• [49]Banks E, Beral V, Bull D, Reeves G, Austoker J, English R, Patnick J, Peto R, Vessey M, Wallis M, Abbott S, Bailey E, Baker K, Balkwill A, Barnes I, Black J, Brown A, Cameron B, Canfell K, Cliff A, Crossley B, Couto E, Davies S, Ewart D, Ewart S, Ford D, Gerrard L, Goodill A, Green J, Gray W: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362(9382):419-427.
• [50]Foster JS, Wimalasena J: Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996, 10(5):488-498.
• [51]Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM: Phosphorylation of Akt (Ser(473)) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004, 64(15):5232-5236.
• [52]Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002, 99(10):6567-6572.
• [53]Dietterich TG: Ensemble methods in machine learning. Multiple Classifier Systems 1857, 2000:1-15.